Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RILVE trial of rilvegostomig versus pembrolizumab with first-line chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma
jRCT2031260594Not yet recruiting
- Start
- Jan 2027
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label trial of rilvegostomig in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by none. Primary endpoint: Change in intratumoural and peripheral immune biomarkers. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
rilvegostomig
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031260594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260594.